Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 72205-183

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 72205-183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bortezomib-carton-label (Bortezomib Carton Label)

This appears to be a description of a medical product, likely a cytotoxic agent for intravenous or subcutaneous use, stored at room temperature and protected from light. It is packaged in a single-dose via, and the accompanying package insert contains dosage and reconstitution information. The product is distributed by Novadoz Pharmaceuticals LLC and was manufactured by MSN Laboratories in India.*

FDA Label Image

Fig-1 (Bortezomib Fig 1)

FDA Label Image

Fig-2 (Bortezomib Fig 2)

This appears to be a chart or graph showing the percentage of patients at risk over time, with a comparison between BMP and MP. There are also indications of a p-value from a log-rank test. The details of the chart are not available, but it seems to be a medical or scientific data visualization.*

FDA Label Image

Bortezomib-fig-5 (Bortezomib Fig 5)

This appears to be a survival analysis chart, displaying the number of patients at risk over time for two different treatments (BRCAP and RCHOP). The median survival for the BRCAP group is unavailable, but the median survival for the RCHOP group has not been reached. The log rank test shows a statistically significant difference in survival between the two treatment groups, with a p-value of less than 0.001. However, without knowing more about the study or the medical condition being treated, it is difficult to provide more context or interpretation.*

FDA Label Image

Bortezomib-fig-6 (Bortezomib Fig 6)

FDA Label Image

Fig-3 (Bortezomib Figure 3)

This is a graph showing the proportion of patients over time who were treated using Bortezomib and Dexamethasone. The y-axis represents the percentage of patients who survived at a specific timepoint, while the x-axis represents the number of days. The p-value from a log-rank test is included in the text as well.*

FDA Label Image

Fig-4 (Bortezomib Figure 4)

This is a table or graph that compares the effectiveness of Bortezomib and Dexamethasone in reducing the proportion of patients in a clinical trial. The results show the number of patients remaining after a certain amount of time and indicate that Bortezomib may be more effective than Dexamethasone, with a p-value of less than 0.057.*

FDA Label Image

Bortezomib-intravenous-sticker (Bortezomib Intravenous Sticker)

Bortezomib for Injection is a medication that is administered intravenously using a 0.9% Sodium Chloride solution. The vial and syringe both require a sticker indicating that they contain Intravenous Bortezomib. For complete instructions on how to use the medication, refer to the Package Insert in Section 2.*

FDA Label Image

Structure (Bortezomib Structure)

FDA Label Image

Bortezomib-subcutaneous-sticker (Bortezomib Subcutaneous Sticker)

This text provides instructions for preparing and administering Bortezomib for Injection, which is a medication used in the treatment of certain types of cancer. It includes information on the proper dilution using a 0.9% sodium chloride solution to achieve a final concentration of 2.5 mg/mL. The text also mentions the option of administering the medication subcutaneously and provides stickers for labeling the vial and syringe. It directs the reader to refer to the package insert for complete instructions.*

FDA Label Image

Bortezomib-vial-label (Bortezomib Vial Label)

Novadoz Pharmaceuticals LLC distributes Bortezomib, a cytotoxic agent, in a single-dose vial containing 35mg of Bortezomib and 35mg of mannitol. The medication should be stored between 15°C to 30°C (59°F to 86°F) and protected from light. The package insert should be consulted for dosage information. Novadoz® MSN Laboratories Private Limited manufactures the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.